Background: Esophageal cancer is the ninth most diagnosed cancer type worldwide and the sixth most common cause of cancer-related deaths worldwide. Gastric cancer is the fifth most diagnosed cancer type worldwide and the fourth leading cause of cancer-related deaths after lung, colorectal, and liver cancers. Aim: Describe the clinical-epidemiological and pathological pattern of gastro-esophageal cancer and evaluate treatment output (survival details). Patients and Methods: This retrospective study included all esophageal, gastroesophageal, and gastric cancer cases presented to the Clinical Oncology Department, Tanta University, between January 2015 and December 2019. Among 8975 patients presented during that period, there were 200 cases of esophageal, gastro-esophageal, and gastric cancer. Their files were revised, and all documented data were classified. Results: Median overall survival for all patients regardless of tumor site and stage was 10 months (95%CI, 7.187-12.813) while median OS for patients who underwent curative surgical approach with the addition of chemotherapy ± RTH, was15 months (95%CI 13.313 – 16.687) and their median DFS was 10 months (95% CI, 8.570 – 11.430) with 1 year OS was 85%, 11 % respectively. All these patients developed recurrence/metastasis. All patients with loco-regional disease who were treated with definitive CCRTH had a median OS18 months (95% CI,16.754 19.246). These patients developed progression with a median PFS of 12 months (95% CI, 11.208 12.792). All patients with metastatic disease treated with palliative intent had median OS and PFS for 5 months (95% CI, 4.404 - 5.592) and 2 MS (95% CI, 1.571 - 2.429), respectively. Conclusion: Gastric cancer ranked first among the patients analyzed in the last five years, followed by esophageal cancer and then gastro-esophageal cancer. Cancer of all three sites is more common in the age group 40-80 years with a median age of 57-60 years and presented mainly in the advanced stage.